Sunny Pharmtech

Sunny Pharmtech EBITDA per Share

The EBITDA per Share of Sunny Pharmtech (6676.TWO) as of Nov 22, 2026 is -1.07 TWD. In the previous year, EBITDA per Share was -0.41 TWD — a change of 164.15% (lower).

EBITDA per Share

-1.07TWD

YoY

164.15%

Last updated:

EBITDA per Share of Sunny Pharmtech is 2024 -1.07 TWD. EBITDA per Share of Sunny Pharmtech was 2023 -0.41 TWD. It decreases by 164.15% lower compared to the previous year.

The Sunny Pharmtech EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-2.11 TWD
Jan 1, 2019
-1.66 TWD
Jan 1, 2020
-0.57 TWD
Jan 1, 2021
-1.29 TWD
Jan 1, 2022
-1.35 TWD
Jan 1, 2023
-0.41 TWD
Jan 1, 2024
-1.07 TWD
The Sunny Pharmtech EBITDA per Share history
YEAREBITDA per ShareYoY
-1.07TWD+164.15%
-0.41TWD-70.00%
-1.35TWD+5.04%
-1.29TWD+128.07%
-0.57TWD-66.01%
-1.66TWD-21.14%
-2.11TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sunny Pharmtech Stock analysis

What does Sunny Pharmtech do? Sunny Pharmtech Inc develops, manufactures, and markets generic and 505(b)2 drug products, primarily targeting the United States market. The company's main products include lectin drug complex (LDC) anesthesia analgesic ointment, neurofibrillary tangle (NFT) anti-urinary tract infection capsules, anti-mitochondrial antibody (AMA) hemostatic lozenges, cyclosporine A (CYA) injections for anemia, and campto (CPT) gynecological injections. These products are sold directly to customers in the United States, generating revenue through pharmaceutical sales. The company focuses on developing and commercializing specialized drug formulations, with its product portfolio centered on LDC, NFT, AMA, CYA, and CPT branded medications. Sales are concentrated in the United States, where the firm's generic and 505(b)2 drug products are marketed to healthcare providers and pharmacies. Revenue is derived from the direct sale of these pharmaceutical products to U.S. customers. Sunny Pharmtech Inc's business model relies on the development and marketing of its proprietary drug formulations, including LDC, NFT, AMA, CYA, and CPT products, which are sold to the United States market. The company's revenue stream is generated through the sale of these branded pharmaceutical products to U.S. healthcare institutions and retail pharmacies. Sunny Pharmtech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sunny Pharmtech stock

EBITDA per Share of Sunny Pharmtech is -1.07 TWD in 2024.

EBITDA per Share of Sunny Pharmtech changed from -0.41 TWD to -1.07 TWD, representing a 164.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Sunny Pharmtech since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Sunny Pharmtech

All Key Metrics — Sunny Pharmtech